Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-6213 · 1 trial · 1 indication
Blood collected at baseline (predose) and after 4 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by reflex beta-quantitation method. The percentage change from baseline at Week 4 was summarized.
| Arm | Type | Description |
|---|---|---|
| MK-6213 160 mg + Atorvastatin 20 mg | EXPERIMENTAL | 1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks |
| Atorvastatin 20 mg | ACTIVE_COMPARATOR | 1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks |
| MK-6213 160 mg | EXPERIMENTAL | 1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks |
| Placebo | PLACEBO_COMPARATOR | 1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks |
| Name | Type | Description |
|---|---|---|
| MK-6213 | DRUG | MK-6213 160 mg for 4 weeks. |
| Atorvastatin calcium | DRUG | atorvastatin calcium 20mg for 4 weeks. |
| Placebo for MK-6312 160 mg | DRUG | - |
| Placebo for Atorvastatin 20 mg | DRUG | - |
Inclusion Criteria: * 18 to 75 years of age at the time of the study with high cholesterol * Can have diabetes mellitus but is not currently on lipid lowering therapy * Have a stable weight for \>6 weeks Exclusion Criteria: * Has significant cardiovascular (heart), renal (kidney), neurologic (ner...
MK-6213 is an investigational small molecule being studied for the treatment of hypercholesterolemia, a condition of high cholesterol levels in the blood. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 2 clinical development.
MK-6213 is a small molecule developed by Merck & Company, Inc. (MRK) for hypercholesterolemia. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its ability to lower cholesterol when co-administered with atorvastatin.
MK-6213 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is an investigational small molecule intended for the treatment of hypercholesterolemia.
MK-6213 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial of MK-6213 has been completed, and the drug is being studied for hypercholesterolemia.
MK-6213 has one completed Phase 2 clinical trial, identified as NCT00687271. This randomized, double-blind, placebo-controlled study evaluated MK-6213 co-administered with atorvastatin in 334 participants with hypercholesterolemia. The trial enrolled adults aged 18 years and older.
MK-6213 is an investigational small molecule developed by Merck & Company, Inc. (MRK) for hypercholesterolemia. It has been studied in combination with atorvastatin, a commonly used statin, but its relationship to other cholesterol-lowering medications has not been disclosed in available clinical trial information.